Chengdu Kanghong Pharmaceuticals Group is a modern medicine enterprise group
headquartered in Chengdu, Sichuan, and consisting of 9 member companies as follows:
. Chengdu Kanghong Pharmaceutical Co., Ltd.,
. Sichuan Jishengtang Pharmaceuticals Co., Ltd.,
. Chengdu Hongda Pharmaceuticals Co., Ltd.,
. Kanghong & Sagent (Chengdu) Pharmaceuticals Co., Ltd.,
. Chengdu Konghong biological Science & Technology Co., Ltd.,
. Shanghai Kanghong Weichi Biotechnology Co., Ltd.,
. Chengdu Phargentech Co., Ltd.,
. Sichuan Kanghong Medicine Trade Co., Ltd.,
. Chengdu Kanghong Medicine Trade Co., Ltd.,
Since the establishment of the Group, the ideal of the enterprise is ‘contribute to the
prosperity of the society and health of the people’, from which the name of the company
is derived. By ‘prosperity’ we mean we aim to create greater values for the country and
people and by ‘health’ we aim to provide better medical service and products. The
company concentrates all resources to engage in the preparation and dealing of the
medicines in psychosis, neurosis, digestion, respiration, incretion and tumors. We are
striving to be one of the most outstanding pharmaceutical companies in China.
Up to now, there are over 2,000 staffs in the Group. It has a modern base covering an
area of over 280,000 m2 for the preparation of natural medicines, chemical medicines,
and biological medicines. Its annual sale reaches RMB 1 billion with the sales network
ranging across China’s all provinces, metropolitans, autonomous regions and
southeastern Asia. Since the establishment of the Group, it has been supported and
directed by the governments at all levels and been loved by people from all walks of life
as well as by the mass of patients. The business scale and economic gains of the Group
has made a rapid progress, resulting in accumulative taxation of over RMB 700 million
paid to the country. Since 2005 it has turned in annual taxation more than RMB 100 in 3
successive years. The Group has been awarded “Important Enterprise with Advantages”
at provincial and city levels in 5 successive years, and was awarded “Industrial Enterprise
with Outstanding Contribution” in Sichuan province in 2006.
Overview---Science and Technology
Kanghong Pharmaceuticals Group has always maintained the development strategy based
on product innovation and technology innovation and moved forward on the road of
specialized development by concentrating on R&D, production and sale of the drugs for
psychosis, neuropathy, respiration, digestion, incretion and tumor and more. As a result
the Group has gradually formed its own core competitive edge. Up to now, the Group has
owned 61 domestic and international invention patents, 4 class-1 in-research new drugs
which are independently developed, and a complete new products marketing planning
which has been extended to 2014.
Konghong Technology Innovation Center also named Enterprise Group Technology
Center (hereinafter shortened as the Technology Center) is a “National-level Enterprise
Technology Center” accredited by five state ministries and commissions including
Development & Reform Commission of the State, Ministry of Science & Technology,
Ministry of Finance, General Taxation Administration of the State, and General Customs
Administration of the State in October, 2006. It was then the only such center ratified by
the state organs in China’s west signifying that the Group had been already on the higher
platform for development. In 2007, the Center successfully passed the reassessment of
the state. Now the Center has established a number of technical platforms for the Chinese
medicines, biological medicines and chemical medicines to meet the demands of the
research for new drugs
In terms of biological medicine innovations, the Center has established the technology
platforms of protein genetic engineering, the genetic therapeutic research & development,
the analysis of disease-related genes, and the mass-production of the biological medicines.
The Center has successfully developed a number of Class-I national new drugs, including
the anti-tumor medicine which is under clinical experiment now and an ophthalmological
genetic medicine for related diseases caused by the eye-ground blood vessels. In addition,
Shanghai Konghong Weichi Biological Medicine Research Center has set up a
technology platform for human-derived mono-colon antibodies. The present in-research
projects are leading in the international standard to provide a solid foundation for the
R&D of the new drugs.
In terms of traditional Chinese medicines and chemical medicines, the Center has set up
advanced technology platforms for screening and selecting medicine sources, for midphase clinical experiment of natural and herbal medicines, for standard preparation
research, and for biological information research. By these platforms more than 20 new
drugs have been successfully developed and marketed. There are still a dozen of inresearch projects carried out in the platforms, including some Class-I new chemical drugs
with new chemical structures, some Class-I new biological drugs, some new preparations
adopting the new-release system of the medical effect, some Chinese or natural
medicines comprising the effective parts of the herbal sources, and some compound
preparations comprising Chinese or natural herbs. All projects in research now own
independent intellectual properties.
Konghong post-doctoral work station was ratified by State Ministry of Personnel in 2000.
Since then a dozen of PhD holders has entered the station to engage in the preliminary
research and screening and evaluation of new drugs as well as the functional mechanism
of the new drugs, etc.
Overview - Production
At present, the group has 4 GMP production bases in the fields of natural medicines,
chemical medicines, traditional Chinese medicines and chemical source medicines. The
bases produce 3 types of source medicine, 8 forms of drugs with 11 varieties. The
products range in the areas of spiritual diseases, neuropathy, digestive, respiratory and
internal secretion, etc.
The production base at the headquarters of the Group possesses the most up-to-date
technology in China to produce the scattering pills and slow-releasing pills, thus leading
in the fields of spiritual, neuropathy and digestive medicine in the country
The Group’s representative products include the “Venlafaxine Hydrochloride Capsule”,
the first of its kind in the world as SNRI anti-depressant drug; the slow-releasing tablet of
venlafaxine hydrochloride (Trade Name: Blossom) by using infiltrating pump technique
and laser-percolating drilling technique; the world-first Aripiprazole Orally
Disintegrating Tablet” (Trade Name: Brisking), a DDS type of drugs of anti-psychosis
disease; the scattered tablet for promoting the peristalsis of stomach and duodenum and
accelerating the gastric dynamos (Trade Name: New Boronia). Blossom was rated as the
National Key New Product in 1999 and listed into the National Catalogues of Basic
Drugs of Medical Insurance. All products mentioned above have all been listed in the
National Torch Project.
Chengdu Kanghong Pharmaceutical Co., Ltd., a branch company of the Group, passed
GMP certification assessment by the State Drug Supervision Administration (SDFA), so
became the first pharmaceutical enterprise to gain GMP system certification in Sichuan
province, and gained the first GMP certificate (No.A0001) issued by the SDFA since its
formation.
The highlighted products of the Group such as ‘Songling Xiemaikang Capsule’, ‘Yiqing
Capsule’, and ‘Zhengkening Capsule’ are listed in the National Catalogues of Basic
Drugs of Medical Insurance and the National Catalogues for the Protected Chinese
Medicine. At the same time ‘Songling Xiemaikang Capsule’ is the listed in the National
Catalogues of Basic Drugs, National Patented New Drug, and National Key New Product.
It was the most selected Chinese medicine in hospitals to depress and modulate the blood
pressures. ‘Yiqing Capsule’, and ‘Zhengkening Capsule’ are also widely used in hospitals
as the major brand to eliminate heat and suppress coughing. The latter was awarded ’ the
Well-known Brand of Sichuan Province”.
As a member company of the Group, Sichuan Jishengtang Pharmaceuticals Co., Ltd. has
always stuck to its traditional principle of “sparing no efforts and sources in making the
medicine”, applied its 80 years’ experience in using rich local resources of natural herbs,
as well as modern production process to produce the quality products.
‘Gankeshuangqing Capsule’ owns the intellectual property right protection for 20 years,
and it is the first high-effect and plant-based drug in China to be specially used in the
treatment of acute upper respiratory infection and acute bronchitis. ‘Danshu Capsule’ was
awarded the gold medal in the National Torch Project and listed in the National
Catalogues of Basic Drugs of Medical Insurance. It is an ideal medicine for gall blander
channel.
As a branch of the Group, Chengdu Kanghong Biological Science & Technology Co. Ltd.
is a brand-new high-tech enterprise specialized in research and development of
biotechnology pharmacy. The research of three Class-I national registered new medicines
is in full operation, including individualized tumor vaccine (KH901), ophthalmologic
genetic engineering pharmacy (KH902) and tumor genetic engineering pharmacy
(KH903). At present the company has successfully established three national-leading
platforms, namely, large-scale virus production and purification platform, large-scale
protein and antibody production and purification platform, tumor vaccine production
technical platform. All these platforms keep the same pace with the international-level.
The individualized tumor vaccine (KH901) utilizes the suspension cell-tissue culture
processing equipment to make the medicine reach the same production level and quality
level of the overseas products, not to mention that it serves a number of overseas and
domestic pharmaceutical enterprises in terms of the production of the related medicines.
In regard to the CHO suspended cell and non-serum culture processing for protein
medicines are leading in the country in terms of the production scale and quantity.
Overview - Service
Trading companies under the Group such as Sichuan Kanghong Medicine Trade Co., Ltd.,
insists on a specialized marketing approach of “establishing own sales network,
practicing strict regulations, surviving by quality, and gaining profits through service.”
The Group regards quality and service as life and operates according to GSP standards to
set up a accomplished quality assurance system. With our efforts of many years, we have
obtained good sales achievement and established a good reputation in social as well as in
industry. Now our sales network covers over 30 provinces, autonomous regions, and
metropolitans and even reaches the southeastern Asia. We are proud of having a highly
specialized team of academic promotion. Not only do we have a team but we also have
an accomplished training system. At present is formed a high-quality, high-efficiency,
and specialized marketing team with professionalism and executive power by our rich
marketing experience, strict management and effective training.
The Group has always assumed as its own obligation to care for the people’s health and
spread health knowledge. In the operation process, we are honest to clients as well as to
society. According to the sales approach of “Academic promotion on the basis of
specialization”, we have been insisting on launching different types of academic
exchanges events by inviting experts from home and abroad to deliver speeches to
medical staff, patients and general public about knowledge of medicine and new drugs so
that they can more effectively and safely use the medicines. We serve as a bridge
between enterprise, doctors, patients and general public.
Overview - Global Strategies
In December, 2006, a joint-venture entitled Kanghong Sagent (Chengdu)
Pharmaceuticals Co., Ltd. was established with total investment over USD 100 millions
by Chengdu Kanghong Technology Industrial (Group) Corporation and American Sagent
Pharmaceuticals, Inc., with each investing 50%. The company is located in the Export
Processing Area of the West Park of Chengdu High & New Technology Industry
Development Zone, covering an area of 170 mu with the first-stage building areas of 50
thousand sq.m. The factory is set up according to state-of-art American GMP standards
with all-encompassing insulation production technology, and will pass SFDA
certification and American FDA certification.
On August 2, 2008, Konghong-Sagent designing mode was assessed in Washington, D.C.,
U.S.A by 6 FDA experts and officials. Having heard about the new designing ideal, they
reckoned this mode might be the first of its kind in Asian-pacific to adopt the total
insulation production line which definitely conforms to the FDA’s ideal of the quality
based on the designing and expressed their hope to see it come into full operation in
China.
It is planned the production base of Kanghong Sagent (Chengdu) Pharmaceuticals Co.,
Ltd. will be in full operation in 2009. The main products comprise three categories, that is,
anti-tumor drugs, anti-infective and daily-use clinical injections. The production scale is
expected to be 300 million product units with the annual production worth USD 1 billion.
All products will be directly sold to the global markets.
In future Kanghong Pharmaceuticals Group shall always maintain our ideal of ‘contribute
to the prosperity of the society and health of the people’ and insist on developing with an
innovative approach. We shall be down-to-earth to strive forward with steady pace so as
to develop more high-quality and high-tech drugs to better serve public health, to
promote progress in pharmaceutical industry, and repay the care from the society.